Orthocell Ltd delivered a standout FY26 with 44% revenue growth to A$13.2 million, powered by accelerating US sales of its nerve repair product Remplir and a robust cash position supporting further expansion.
- FY26 revenue rises 44% to A$13.2 million
- US Remplir sales reach A$0.33 million in Q4, ahead of forecasts
- Distributor network covers 50% of US population across 20+ states
- Strong cash reserves of A$44.1 million underpin growth strategy
- EU/UK regulatory clearance expected in second half of 2026
US Remplir Sales Outperform Expectations
Orthocell Ltd (ASX:OCC) has accelerated its US commercialisation of Remplir, its flagship nerve repair device, with quarterly sales hitting A$0.33 million in Q4 FY26. This marks a significant milestone since the product's US launch in June 2025, with cumulative sales now approaching A$0.92 million. The company’s distributor network has expanded rapidly, now covering approximately 50% of the US population across more than 20 states, a 25% overshoot of initial targets.
Hospital adoption is gaining traction, with 70 hospitals having purchased Remplir units and over 100 Value Assessment Committee (VAC) approvals submitted or approved. Surgeon engagement is similarly strong, with 76 surgeons having used Remplir, well exceeding early expectations. These figures reflect compound quarterly growth rates of nearly 200% in hospitals, surgeons, and unit sales since launch, underscoring robust market uptake.
Record Revenue and Solid Cash Position
Orthocell reported record FY26 revenue of A$13.2 million, up 44% year-on-year, with Q4 alone contributing A$3.8 million, a 20% increase over the prior quarter. The surge is primarily driven by Remplir sales, which accounted for the majority of growth, supplemented by ongoing demand in Australia and Asia-Pacific markets.
The company maintains a strong balance sheet with A$44.1 million in cash and term deposits, no long-term debt, and no royalty liabilities. This liquidity supports a cash runway of approximately 4.6 years, enabling sustained investment in sales growth, manufacturing capacity expansion, and research and development activities. Operating cash burn remains stable quarter-on-quarter after adjusting for annual R&D tax incentives and one-off expenditures.
Global Expansion and Pipeline Progress
Orthocell’s international footprint continues to broaden. The company has secured distribution in Australia, New Zealand, Canada, Singapore, Hong Kong, and Thailand, with the latter recently appointing MediTime as an exclusive distributor, strengthening its Asia-Pacific presence. The EU and UK regulatory submissions for Remplir are on track for clearance in the second half of calendar 2026, opening access to a sizeable new market.
Beyond nerve repair, Orthocell is advancing its product pipeline with the initiation of a US FDA regulatory program for SmrtWrap, targeting tendon repair applications. Additionally, early commercial opportunities in nerve-sparing prostate cancer surgery are gathering momentum, with initial patient data expected in the latter half of 2026.
Outlook and Commercial Targets for FY27
Looking ahead, Orthocell aims to increase its US distributor coverage to 80% of the population, extending into over 30 states. The company targets 100-150 hospitals and 150-200 surgeons actively using Remplir by the end of FY27, reflecting a clear strategy to deepen market penetration and drive revenue growth. The company’s cash position and operational momentum position it well to achieve breakeven as sales scale.
While the US remains the primary growth engine, Orthocell’s global initiatives and pipeline developments could unlock further value, though regulatory timelines and market adoption rates inherently carry uncertainty.
Bottom Line?
Orthocell’s robust US sales momentum and strong cash reserves set the stage for potential breakeven and accelerated growth, contingent on sustained market adoption and timely regulatory clearances.
Questions in the middle?
- Can Orthocell sustain its rapid US hospital and surgeon adoption rates beyond early growth?
- How will upcoming EU/UK market entry impact revenue diversification and scale?
- What are the prospects and timelines for SmrtWrap’s regulatory approval and commercial launch?